- 01TACTI-004 Phase III trial for eftilagimod alfa in NSCLC discontinued due to futility.
- 02Company forecasts extended cash runway beyond Q2 CY2027 following trial termination.
- 03Shares reinstated to quotation; persistent funding and clinical risks remain key investor concerns.
Immutep (ASX: IMM) announced the discontinuation of its TACTI-004 Phase III trial in first-line non-small cell lung cancer (NSCLC) due to futility, a significant setback that presents a complex picture for investors regarding the company's lead candidate and future cash runway.
The Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial due to futility. This trial was evaluating eftilagimod alfa in first-line NSCLC.
Enrolment for the trial has been halted, and an orderly wind-down process will commence.
The TACTI-004 trial was designed to assess eftilagimod alfa, in combination with pembrolizumab and chemotherapy, against a placebo control arm of pembrolizumab and chemotherapy.
This trial had an expected enrolment of approximately 756 patients across around 150 sites in over 25 countries, and the discontinuation raises questions about eftilagimod alfa's commercial potential.
Extended Cash Runway Forecasted
Despite the clinical setback, Immutep anticipates its cash runway will extend well beyond the previous guidance of Q2 CY2027.
This extension is a direct result of the discontinuation of the TACTI-004 trial.
The company plans to provide an updated cash runway outlook once it completes a full data analysis and operational assessments.
Immutep's shares were reinstated to quotation immediately following the announcement regarding the outcome of the interim futility analysis for the TACTI-004 trial.
The company had earlier requested and received a voluntary suspension from quotation, which followed an initial trading halt, to prevent uninformed trading while awaiting the crucial futility analysis results.
Persistent Funding and Clinical Risks
Immutep continues to face substantial operating losses, recording a net loss of A$61.4 million in FY2025, up from A$42.7 million in FY2024, highlighting the company's ongoing funding needs.
Future research and development and clinical trial costs are expected to rise.
Immutep anticipates needing additional financing through equity, debt, or licensing arrangements to support its programs.
The company also navigates significant clinical development and regulatory approval risks.
Success in preclinical or early-stage trials does not guarantee success in later stages or regulatory approval.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.